Health services merger and acquisition activity remains active in the first months of 2026, but uncertainty around regulations, interest rates, and valuations is keeping overall deal volume from rising as high as some industry observers expected. That is the key finding of a new report from PwC, as covered by Healthcare Dive.

The report suggests that while strategic buyers and private equity firms continue to pursue deals, they are proceeding with more caution than in previous years. The result is a market that is lively but not booming, with many deals taking longer to close.

Key takeaways from the PwC report

  • Health services M&A activity in early 2026 is described as “active” by PwC, but the pace of deals remains below the volume seen in some prior years.
  • Uncertainty around federal healthcare policy, antitrust enforcement, and interest rate direction is prompting many buyers to take a more measured approach.
  • Valuation gaps between buyers and sellers are narrowing, but still exist, which can slow negotiations.
  • Private equity involvement remains significant, though firms are focusing on add-on acquisitions rather than large platform deals.
  • Strategic buyers, including health systems and payers, are selectively pursuing deals that strengthen their market positions or improve operational efficiency.

Why uncertainty is restraining deal volume

The PwC report, according to Healthcare Dive, points to several overlapping sources of uncertainty that are weighing on M&A activity. Regulatory uncertainty tops the list. Ongoing changes to federal healthcare reimbursement models, potential shifts in antitrust policy under the current administration, and evolving state-level oversight all make it difficult for buyers to predict the long-term financial impact of an acquisition.

Economic factors also play a role. While interest rates have stabilized compared to the sharp increases of prior years, borrowing costs remain elevated. This influences deal financing and return expectations, particularly for private equity firms that rely on debt to fund acquisitions. In addition, lingering inflation in labor and supply costs makes it harder to model post-deal synergies.

Deal focus: adding capabilities and scale

According to the PwC analysis, the deals that are getting done tend to fall into two main categories. The first involves acquisitions that add new service lines or capabilities, such as behavioral health, home health, or digital health tools. The second category includes transactions that build geographic scale, especially in outpatient and ambulatory care settings.

Buyers are showing a clear preference for targets that have stable cash flows, strong management teams, and clear paths to integration. Large, transformative “megadeals” remain rare, as the current environment does not favor the kind of bold bets seen in previous M&A cycles.

Private equity’s cautious approach

Private equity firms continue to be active players in health services M&A, but their strategy has shifted. Rather than pursuing large platform investments, they are focusing on add-on acquisitions to existing portfolio companies. This approach allows them to grow value while limiting exposure to regulatory and market risks.

The report also notes that exit activity, such as selling portfolio companies or taking them public, has been slower than expected. This creates a “logjam” of assets awaiting sale, which could eventually lead to a surge in deals once uncertainty recedes.

Outlook for the rest of 2026

PwC’s report anticipates that M&A activity will remain at a moderate pace for the remainder of 2026, barring major shifts in policy or the economy. If regulatory clarity improves and interest rates ease further, deal volume could accelerate in the second half of the year. However, if uncertainty persists, many potential transactions may be delayed or restructured.

Healthcare Dive notes that industry stakeholders will be watching for signals from federal regulators, the Federal Reserve, and Congress as they shape the environment for future health services M&A.

Frequently Asked Questions

What does “active but uncertain” mean for health services M&A in 2026?

According to the PwC report, the phrase refers to a market where buyers and sellers remain engaged and deals are being made, but overall volume is lower than it could be because of unresolved questions about healthcare policy, interest rates, and valuations. Many deals are taking longer to negotiate and close.

Which types of health services companies are most attractive to buyers in 2026?

The report indicates that buyers are especially interested in companies that offer behavioral health, home health, digital health solutions, and outpatient care services. Targets with stable revenues, strong management, and clear integration potential are preferred. Large, risky platform deals are less common.

Could health services M&A volume pick up later in 2026?

Yes, PwC suggests that if regulatory and economic uncertainties ease, deal volume could increase in the second half of 2026. A backlog of assets awaiting sale may also drive a surge once conditions become more favorable. However, the pace of recovery depends on external factors that are difficult to predict.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.